The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial
Open Access
- 7 February 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Medicine
- Vol. 17 (2), e1003033
- https://doi.org/10.1371/journal.pmed.1003033
Abstract
Assessing genetic lifetime risk for prostate cancer has been proposed as a means of risk stratification to identify those for whom prostate-specific antigen (PSA) testing is likely to be most valuable. This project aimed to test the effect of introducing a genetic test for lifetime risk of prostate cancer in general practice on future PSA testing. We performed a cluster randomized controlled trial with randomization at the level of general practices (73 in each of two arms) in the Central Region (Region Midtjylland) of Denmark. In intervention practices, men were offered a genetic test (based on genotyping of 33 risk-associated single nucleotide polymorphisms) in addition to the standard PSA test that informed them about lifetime genetic risk of prostate cancer and distinguished between “normal” and “high” risk. The primary outcome was the proportion of men having a repeated PSA test within 2 years. A multilevel logistic regression model was used to test the association. After applying the exclusion criteria, 3,558 men were recruited in intervention practices, with 1,235 (34.7%) receiving the genetic test, and 4,242 men were recruited in control practices. Men with high genetic risk had a higher propensity for repeated PSA testing within 2 years than men with normal genetic risk (odds ratio [OR] = 8.94, p < 0.01). The study was conducted in routine practice and had some selection bias, which is evidenced by the relatively large proportion of younger and higher income participants taking the genetic test. Providing general practitioners (GPs) with access to a genetic test to assess lifetime risk of prostate cancer did not reduce the overall number of future PSA tests. However, among men who had a genetic test, knowledge of genetic risk significantly influenced future PSA testing. This study is registered with ClinicalTrials.gov, number NCT01739062.Funding Information
- Strategiske Forskningsråd (10-092796)
- Sector skills council for quality and postgraduate training (1-30-72-93)
- Kræftens Bekæmpelse
- Velux Fonden
This publication has 35 references indexed in Scilit:
- General Practice and Primary Health Care in DenmarkThe Journal of the American Board of Family Medicine, 2012
- Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort StudyEuropean Urology, 2011
- Danish education registersScandinavian Journal of Public Health, 2011
- The impact of PSA testing frequency on prostate cancer incidence and treatment in older menProstate Cancer and Prostatic Diseases, 2011
- Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease RiskThe New England Journal of Medicine, 2011
- Do Men Make Informed Decisions about Prostate Cancer Screening? Baseline Results from the “Take the Wheel” TrialMedical Decision Making, 2010
- American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010CA: A Cancer Journal for Clinicians, 2010
- Prostate cancerThe Lancet, 2008
- Trials of Decision Aids for Prostate Cancer Screening: A Systematic ReviewAmerican Journal of Preventive Medicine, 2007
- The GRAIDS Trial: a cluster randomised controlled trial of computer decision support for the management of familial cancer risk in primary careBritish Journal of Cancer, 2007